20 April 2023 in Expert Opinion on Drug Safety
T-DM1 and T-DXd are two promising antibody-drug conjugates for treating advanced HER2-positive breast cancer and HER2-mutated lung cancer. Understanding the differences in the adverse events (AEs) ...
21 March 2023 in Journal of Global Antimicrobial Resistance
Generic medications are widely used because of their low cost. However, some generic medications show lower quality and clinical efficacy compared with brand-name medications, especially for antimicrobial drugs. Levofloxacin is a fluoroquinolone antimicrobial drug with excellent antimicrobial activity and wide antimicrobial spectrum, while it is susceptible to drug resistance. Our study aims to evaluate the bioequivalence of generic and brand-name levofloxacin. The pharmacokinetic (PK) parameters (Cmax, AUC0∼24, Tmax, and t1/2), pharmacodynamic (PD) parameters (in vitro antibacterial activity and the inhibition of resistant mutation), and PK/PD analysis (the probability of target attainment; the cumulative fraction of response) calculated by Monte Carlo simulation were investigated. Our results demonstrated that compared with generics, brand-name levofloxacin not only had higher drug content, it also showed higher antimicrobial susceptibility, higher resistance to mutation ability, and higher percentage of each dosage interval wherein plasma concentration of antimicrobial agents exceeded the MPC90 (mutant prevention concentration to prevent the mutation of 90% strains) against various clinical isolates. Although the differences in AUC0∼24 between brand-name levofloxacin and generics were not statistically significant (P > 0.05, F test), Monte Carlo simulation results showed cumulative fraction of response values for PK/PD of brand-name medications were higher than generics. Our results indicated that PK or PD equivalence did not imply therapeutic equivalence; thus, we suggest including PK/PD analysis in the bioequivalence evaluation system, which benefits prediction of clinical outcome with high application value.
1 January 2025 in Pain Research and Management
Objective: Pain is one of the most common and long‐lasting symptoms after lung cancer surgery, potentially impairing physical functioning. This study aims to investigate to what extent pain mediates the association between the different surgical approaches (single‐port VATS versus multiport VATS or thoracotomy) and postoperative functional recovery after lung cancer surgery, with the goal of establishing clinically actionable pain score thresholds. Methods: In a prospective cohort study including 1381 patients, pain and functional status (activity limitation and walking difficulty) were assessed daily in hospital with the Perioperative Symptom Assessment for Lung Surgery (PSA‐Lung). The structural equation model (SEM) was used to investigate the mediation effect of pain in the surgery–pain–functioning pathway. The pain thresholds on postoperative day (POD) 1, 2, and 3 for optimal functional recovery were identified, corresponding to the cutoff points of pain categorization that demonstrated the largest indirect effects in the models. Results: The surgical approach had a significant indirect effect on activity limitation and walking difficulty through pain severity ( p < 0.001), with a standardized effect value of 0.039 and 0.037, respectively. According to the largest mediation effects of pain categories generated from the each day SEM, the optimal pain score cutoffs are 5 on POD1, 4 on POD2, and 3 on POD3, for both activity limitation and walking difficulty. Conclusion: Our study quantified the partial mediating effects of pain between surgical approaches and postoperative functional status in patients with lung cancer surgery. The mediation effect–based pain thresholds support precise strategies for postoperative functional rehabilitation, which is considered the major goal of enhanced recovery after surgery. Trial Registration: Chinese Clinical Trials Registry: ChiCTR2000033016